Prosecution Insights
Prosecution Insights
Tech Center 4100 • Art Units: 1635 1674 4100
This examiner grants 64% of resolved cases
Terra C. Gibbs works in Tech Center 4100 and Art Unit 1635, with 968 resolved cases. The allowance rate is 63.7%, and the median days to allowance is 994. These metrics suggest a moderate success rate and a typical timeline for grant. The 63.7% rate is the primary benchmark for success, while the 994-day figure defines the expected duration of the prosecution process. Practitioners should use these figures to set expectations for applications in this art unit.
The interview lift is 10.3%, which is a modest increase over the 63.7% allowance rate. This 10.3% lift indicates that while interviews are helpful, they are not as transformative as in other profiles. With 968 resolved cases, the data reflects a consistent pattern of behavior. Practitioners should consider the 994-day median and the 10.3% lift when deciding whether to initiate an interview. These metrics provide a reliable basis for strategic planning with this examiner.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17439439 | Therapeutic Targets for Oncogenic KRAS-Dependent Cancers | Non-Final OA | University of Massachusetts |
| 18256805 | REGULATORY ELEMENTS FOR SCHWANN CELL-SPECIFIC GENE EXPRESSION | Final Rejection | Wisconsin Alumni Research Foundation |
| 18289418 | MIRNA INHIBITORS FOR PREVENTING AND TREATING ANEURYSMS, HYPERTENSION, ARDS AND OTHER DISEASES ASSOCIATED WITH ENDOTHELIAL DYSFUNCTION | Non-Final OA | The Regents of the University of California |
| 18280126 | METHODS OF MODULATING NEURONAL AND OLIGODENDROCYTE SURVIVAL | Non-Final OA | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY |
| 18052897 | COMPOSITIONS AND METHODS OF TREATING POMPE DISEASE | Non-Final OA | Avidity Biosciences, Inc. |
| 17794920 | COMPOSITIONS AND METHODS TO TREAT NEUROLOGICAL DISEASES | Non-Final OA | University of Southern California |
| 18431197 | METHODS AND COMPOSITIONS FOR MODULATING APPETITE AND INTAKE OF SODIUM | Final Rejection | California Institute of Technology |
| 18271782 | LIPID NANOPARTICLE SPHERICAL NUCLEIC ACIDS | Non-Final OA | NORTHWESTERN UNIVERSITY |
| 17920752 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | Final Rejection | Flagship Pioneering Innovations VI, LLC |
| 17920769 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | Final Rejection | Flagship Pioneering Innovations VI, LLC |
| 18149520 | METHODS AND COMPOSITIONS FOR REDUCING IMMUNOSUPPRESSION BY TUMOR CELLS | Non-Final OA | The General Hospital Corporation |
| 18287048 | USE OF ODORANT RECEPTOR FOR SUPPRESSING LACTATE-INDUCED M2-TYPE DIFFERENTIATION OF TUMOR-ASSOCIATED MACROPHAGES AND TUMOR GROWTH | Non-Final OA | DAEGU GYEONGBUK INSTITUTE OF SCIENCE AND TECHNOLOGY |
| 18259098 | VIRAL CAPSID PROTEINS WITH SPECIFICITY TO HEART TISSUE CELLS | Non-Final OA | Boehringer Ingelheim International GmbH |
| 18560347 | COMPOSITIONS AND METHODS OF TARGETING THE PAX6 SIGNALING PATHWAY TO REDUCE FORMATION OF AMYLOID BETA PLAQUES AND NEUROFIBRILLARY TANGLES | Non-Final OA | The University of Hong Kong |
| 18637183 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE LECT2 GENE | Final Rejection | ALNYLAM PHARMACEUTICALS, INC. |
| 18542950 | METHODS AND COMPOSITIONS FOR TREATING AN ANGIOTENSINOGEN- (AGT-) ASSOCIATED DISORDER | Non-Final OA | Alnylam Pharmaceuticals, Inc. |
| 18215849 | COMPLEMENT COMPONENT 9 (C9) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | Non-Final OA | Alnylam Pharmaceuticals, Inc. |
| 18653869 | COMPOSITIONS AND METHODS OF ALLEVIATING RESISTANCE TO CHEMOTHERAPY | Non-Final OA | CITY OF HOPE |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy